Biogen Idec Ma Inc.

Biogen Ma Inc.

Curis, Inc.

Ucb Biopharma Sprl

Other

Ucb Pharma, S.a.

Biogen Idec, Inc.

Biogen International Neuroscience Gmbh

Werner Meier

Laura Silvian

R. Blake Pepinsky

Alexey Lugovskoy

Dingyi Wen

Paul H. Weinreb

Xinzhong Wang

Ellen A Garber

Jose William Saldanha

Frederick Robbins Taylor

Antonin De Fougerolles

R Blake Pepinsky

Victor E Kotelianski

Carl Reid

Alexey Alexandrovich Lugovskoy

Paul D Lyne

Linda C Burkly

Christilyn Graff

Paul H Weinreb

Ralph Adams

Kerry Louise Tyson

Andrew George Popplewell

Yen-Ming Hsu

Scott Glaser

Martyn Kim Robinson

Kevin P Williams

Derek Thomas Brown

Herman Van Vlijmen

Jeffrey L Browning

Sha Mi

Jeffrey A Porter

Stephen John Demarest

Christopher L Reyes

Zhaohui Shao

Russell Colyn Petter

Justin Andrew Caravella

Jan Grimm

Christopher D Benjamin

Michael Karpusas

Lihe Su

Janine L Ferrant-Orgettas

Anthony Shock

Kandasamy Hariharan

Daniel H S Lee

Veronique Bailly

Darren P Baker

Jane K Relton

Steven Donald Miklasz

Kathryn Strauch

Alphonse Galdes

Antonin R De Fougerolles

Kenneth J Simon

Michele Sanicola-Nadel

Xiufeng Wu

Fabio Montrasio

Paul Rayhorn

Feng Chen

Graham K Farrington

John K Eldredge

Alexey Lugovsky

Chenhui Zeng

Amna Saeed-Kothe

Steven D Miklasz

Daniel HS Lee

Daniel Hs Lee

The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.

Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto

Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

Human anti-tau antibodies

This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Nogo receptor antagonists and methods of increasing neurite outgrowth

The invention provides antibodies that bind to a plurality of &#x3b2;-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.

Antibodies against monocyte chemotactic proteins

Nogo receptor antagonists

The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto

Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

Sp35 antibodies and uses thereof

The invention provides humanized antibodies that bind to a plurality of &#x3b2;-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.

Humanized antibodies against monocyte chemotactic proteins

Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins

Variants of hedgehog protein that contain N-terminal modifications are described that can block hedgehog function; thus allowing these variants to serve as functional antagonists. These peptides have a primary amino acid sequence lacking the ability to elicit a hedgehog-dependent response in C3H 10T1/2 cells but having the ability to bind to the hedgehog receptor, patched-1. Methods for producing such functional antagonists and methods of using the functional antagonists are also described.

Functional antagonists of hedgehog activity

The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.

Nucleic acids encoding antibodies having altered effector function and methods for making the same

The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.

Anti-IGR-1R antibodies and uses thereof

Growing community of inventors

Cambridge, MA, United States of America

Ellen A Garber